# The Novel Psychoactive Substances Epidemic: a Scientometric Perspective

Michelle Jin Yee Neoh<sup>a</sup>, Alessandro Carollo<sup>b</sup>, Mengyu Lim<sup>a</sup>, Ornella Corazza<sup>b,c</sup>, Aurora Coppola<sup>d</sup>, Gianluca Esposito<sup>b,\*</sup>

<sup>a</sup>Psychology Program, Nanyang Technological University, Singapore, 639818, Singapore <sup>b</sup>Department of Psychology and Cognitive Science, University of Trento, Rovereto, TN, 38068, Italy <sup>c</sup>School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United

Kingdom

<sup>d</sup>Psychology Unit, Azienda Provinciale per i Servizi Sanitari, Trento, Italy, Rovereto, TN, 38068, Italy

## Abstract

The unprecedented proliferation of novel psychoactive substances (NPS) in the illicit drug market has been a public health concern since their emergence in the 2000s. Their consumption can pose a severe health risks as their mechanism of action is poorly understood and their level of toxicity is high mainly due to the diffusion of very potent synthetic cannabinoids and synthetic opioids. This study systemically analyses the evolution of the scientific literature on NPS to gain a better understanding of the areas of major research interests and how they interlink. Findings indicate that the published evidence covers clusters focused on classes of NPS that have received widespread media attention, such as mephedrone and fentanyl, and have largely been concerned with the pharmacological and the toxicological profiles of these substances. This scientometric perspective also provides greater insight into the knowledge gaps within this new and rapidly growing field of study and highlights the need for an interdisciplinary approach in tackling the NPS epidemic.

*Keywords:* document co-citation analysis, novel psychoactive substances, substance use, synthetic cannabinoids, synthetic opioids

Preprint submitted to MedRxiv

October 16, 2022

<sup>\*</sup>Correspondence: Corso Bettini 31, Rovereto, TN, 38068, Italy.

Email address: gianluca.esposito@unitn.it (Gianluca Esposito)

# 1 1. Introduction

In recent years, there has been an unprecedented proliferation of novel 2 psychoactive substances (NPS) in the drug market globally with 1124 sub-3 stances being reported to the United Nations Office on Drugs and Crime by December 2021 [1]. The term NPS is typically used to refer to substances 5 originally designed as legal alternatives to controlled substances, such as analogues of existing controlled drugs and pharmaceutical products designed to mimic their actions and effects [2, 3]. The emergence of NPS in the illicit drug market poses a serious challenge for drug policy and public health. The 9 ease and speed with which NPS are continuously developed and reintroduced 10 in the market as analogues or derivatives with small chemical changes in or-11 der to circumvent drug enforcement and legislation makes these substances 12 difficult to legally regulate and control. In addition, the potency, pharma-13 cological effects and risk profiles of NPS are diverse and generally unknown, 14 where users are often misinformed and lack awareness of the contents of the 15 NPS they are consuming. The properties and long-term effects of NPS are 16 not well understood and few studies examining most of these new substances 17 have been published [4]. 18

19

Adverse health effects including suicide and fatalities have been docu-20 mented in association with and attributed to NPS use [5] and the most 21 frequent classes of NPS are associated with medical risks [6]. In an analysis 22 of hospital emergency data by the European Drug Emergencies Network, 9% 23 of all drug-related emergencies involved NPS [7]. Reports have also cited 24 correlations between NPS use and increased spread of diseases such as HIV 25 and hepatitis C [8]. Although case reports and case series form the bulk of 26 research informing our understanding of NPS, it is apparent that there are 27 significant health risks associated with NPS use. 28

29

Although the prevalence of NPS in the general population appears to be low, their consumption among younger age groups is higher and warrants concern. A systematic review found that most studies showed 3% or less of adult populations reported recent use of NPS, typically in the past year, compared to an estimated 1 in 10 young people [9]. Similarly, an estimated 1-8% of school students have used NPS at some point [10], indicating a wor-

<sup>36</sup> rying trend of drug use among youth. However, it is important to note that <sup>37</sup> such self-report data on NPS use are most likely not an accurate representa-<sup>38</sup> tion of actual market penetration and user uptake of NPS due to the sheer <sup>39</sup> speed in which NPS are introduced to market as well as unwitting consumers. <sup>40</sup>

The aim of this study is to identify the most relevant publications, the 41 nature of their inquiry and associate literature gaps in the field of NPS. 42 We conducted a document co-citation analysis (DCA) [11, 12] to analyse 43 references and the relevance of these publications in the existing literature 44 on NPS. By clustering publications according to common research domains, 45 articles with significant contributions to the literature can be identified while 46 highlighting the coverage and gaps in existing literature. The scientometric 47 results can illuminate research and identifying publication trends, the links 48 between different works and scientific fields involved in the exploration of 40 issues relating to NPS. The scientometric approach has been employed in 50 neuroscience [13] and digital psychology [14]. 51

#### <sup>52</sup> 2. Material and Methods

Publications were downloaded from Scopus in accordance with the stan-53 dard and established scientometric procedures [11]. We used the following 54 search string TITLE-ABS-KEY("novel psychoactive substanc\*" OR "new 55 psychoactive substanc<sup>\*</sup>") AND (LIMIT-TO (LANGUAGE, "English")) 56 and found a total of 2,365 documents published from 1 January 2010 to 13 57 June 2022. By limiting the search to publications in English, the analysis 58 will be built on international scientific literature in the field, allowing for a 59 more standardised and rigorous examination of existing work [15]. 60

# 61 2.1. Data import on CiteSpace

Scientometric analysis was conducted using CiteSpace software (Version 62 (6.1.R2) and the articles downloaded from Scopus were imported into the 63 software. 106,911 of a total of 111,855 references (95.58%) cited by the 2,36564 articles were valid (Figure 1). A "valid" reference is one that contains seven 65 key pieces of information: author, year of publication, title, source, volume, 66 pages and DOI [11]. Due to irregularities in the citation format, a number 67 of references were considered invalid. Negligible losses in references (1-5%)68 commonly occur during the data import to the CiteSpace software [16]. The 69

- <sup>70</sup> CiteSpace function (Remove Alias) was turned ON to eliminate repeated or
- <sup>71</sup> identical entries.




Figure 1: PRISMA flowchart for search criteria and reference eligibility

## <sup>72</sup> 2.2. Document Co-Citation Analysis (DCA) and Optimisation of Parameters

DCA was conducted to determine the main research domains in NPS literature. DCA is based on the frequency with which two or more papers are cited together in source articles [17]. The assumption is that frequent co-citations among articles reflect common research trends and intellectual domains in the literature [12, 18]. The network resulting from the DCA is composed of documents frequently cited together along with the documents that cite them (i.e. articles downloaded from Scopus).

<sup>80</sup> DCA parameters were optimised in order to obtain a balanced network <sup>81</sup> of documents. Several DCAs were computed and compared, each with a <sup>82</sup> different setting for one of three node selection criteria; g-index, TOP N, <sup>83</sup> TOP N%, as done in [13, 15, 18, 19, 14, 20]. The node selection criteria <sup>84</sup> are *a priori* settings that define the criterion used for selecting articles to be

included in the network, and consequently, determine the final network of articles being generated. The g-index is a measure of the citation scores of an author's top publications [21, 22]. It represents the largest number that equals the average number of citations of the most highly cited g publications [16]. TOP N and TOP N% are criteria used to select N and N% most cited within a time slice (1 year was used in this study) as network nodes respectively [11].

In order to generate the final optimal network, node selection criteria were 92 varied together with their scale factor values, which refer to the chosen nu-93 meric values used as thresholds for the respective node selection criteria [14]. 94 Specifically, DCAs with the following node selection criteria were compared: 95 g-index with scale factor k set at 10, 15, 25, 50, TOP N with scale factor N 96 set at 25, 50 and TOP N% with scale factor N set at 10. To determine the 97 node selection criteria and scale factor to use for the generation of the final 98 network, the overall effects on the structural metrics of the generated net-99 work, the number of nodes included and clusters identified were compared. 100 After comparison of these metrics, TOP N with N at 25 was the parameter 101 which was used to generate the final network of articles. 102

# 103 2.3. Metrics

Structural and temporal metrics are used in describing CiteSpace results. 104 Structural metrics consist of (i) modularity-Q, (ii) silhouette scores and (iii) 105 betweenness centrality. Modularity-Q values range from 0 to 1 and indicates 106 the degree to which the network can be decomposed into single groups of 107 nodes, which are referred to as modules or clusters [23]. High modularity-108 Q values indicate a well-structured network [12]. Silhouette scores are a 109 measure of inner consistency - cohesion and separation - of the modules [24]. 110 Silhouette scores vary from -1 to +1, where higher values represent high 111 separation from other modules and internal consistency [25]. Betweenness 112 centrality represents the degree to which a node connects an arbitrary pair of 113 nodes in the network [11, 26]. Betweenness centrality values range from 0 to 114 1, where groundbreaking and revolutionary works in the scientific literature 115 typically score higher [27]. 116

<sup>117</sup> Temporal metrics consist of (i) *citation burstness* and (ii) *sigma*. The <sup>118</sup> Kleinberg's algorithm [28] is used to calculate citation burstness, which in-<sup>119</sup> dicates a sudden increase in the number of citations of an article in a given <sup>120</sup> time frame [29]. Sigma is calculated with the equation (centrality + 1)<sup>burstness</sup>

and indicates the novelty of a document and influence on the overall network[30].

The overall configuration of the generated network and identified clusters of references were examined with modularity-Q and silhouette scores. The attributes of single nodes in the network were examined using betweenness centrality and the temporal metrics.

# 127 3. Results

#### 128 3.1. Structural metrics

The final optimised network obtained from the DCA consisted of 317 nodes and 1,327 links, indicating an average of 4.15 connections with other references for each node (Figure 2). The network had a modularity-Q index of 0.6181 and a mean silhouette score of 0.8445, indicating medium divisibility of the network into clusters that are highly homogenous.




Figure 2: Network of publications generated through the document co-citation analysis (DCA). The major clusters are grouped by colour.

## 134 3.2. Citation burstness

A total of 64 documents were found to exhibit a citation burstness (Table 1). 20 of these documents belong to cluster #0, 13 to cluster #1, 16 to cluster #2, 4 to cluster #3, 3 to cluster #4, 1 to cluster #5, 4 to cluster #6 and 1 to cluster #9. The article with the highest burst strength was authored by Hondebrink et al. in 2015 [31] with a score of 12.43. The burst began in 2017 and ended in 2019. The article with the longest burst duration was

<sup>141</sup> authored by Castaneto et al. in 2014 [32] with a burst duration of 5 years <sup>142</sup> from 2017 to 2022. The article with the highest sigma value was authored <sup>143</sup> by Hermanns-clausen in 2013 [33] with a sigma value of 2.44.

	1				0		
Reference	Burst	Year	Start of burstness	End of burstness	Burst duration	Centrality	Sigma
Hondebrink et al. [31]	12.43	2015	2017	2019	2	0.01	1.10
Armenian et al. [34]	11.68	2018	2019	2022	3	0.02	1.19
Peacock et al. [9]	10.97	2019	2020	2022	2	0.01	1.08
Brandt et al. [35]	10.93	2014	2016	2017	1	0.00	1.00
Rickli et al. [36]	10.58	2015	2017	2018	1	0.00	1.04
Morris et al. [37]	10.07	2014	2017	2018	1	0.05	1.67
Measham et al. [38]	9.46	2011	2012	2014	2	0.07	1.90
Hermanns-clausen et al. [33]	9.44	2013	2014	2017	3	0.01	2.44
Kraemer et al. [39]	8.62	2019	2020	2022	2	0.02	1.17
Seely et al. [40]	8.51	2012	2015	2018	3	0.04	1.41
Richter et al. [41]	8.26	2017	2019	2020	1	0.00	1.01
Baumann et al. [42]	7.92	2012	2016	2017	1	0.01	1.09
Prosser et al. [43]	7.81	2012	2016	2017	1	0.17	3.50
Majchrzak et al. [44]	7.68	2018	2020	2022	2	0.01	1.12
Favretto et al. [45]	7.55	2013	2015	2017	2	0.01	1.10

Table 1: Top 15 publications in terms of burst strength.

#### 144 3.3. Thematic clusters

Ten major clusters were identified (Figure 2, Table 2). The largest cluster 145 #0 consisted of 59 nodes and had a silhouette score of 0.716, where the 146 constituent references were published in 2019 on average. The cluster was 147 labelled "Mechanisms of NPS action". Second, cluster #1 consisted of 56 148 nodes and had a silhouette score of 0.84, where the constituent references 149 were published in 2012 on average. The cluster was labelled "Availability and 150 use of NPS". Third, cluster #2 consisted of 49 nodes and had a silhouette 151 score of 0.809, where the constituent references were published in 2014 on 152 average. The cluster was labelled "Neuropharmacology of NPS". 153

Table 2: Metrics of the 10 clusters identified with the DCA. Log-likelihood Ratio (LLR) labels are automatically generated by the software.

Cluster ID	Size	Silhouette	Mean year	LLR label	Proposed label
0	59	0.716	2019	Synthetic cannabinoid	Mechanisms of NPS action
1	56	0.840	2012	Psychoactive substance	Availability and use of NPS
2	49	0.809	2014	Acute recreational drug toxicity	Neuropharmacology of NPS
3	34	0.820	2016	Strida project	Intoxication profile and detection of NPS use
4	26	0.994	2020	New synthetic opioid	New synthetic opioids
5	18	0.992	2012	Legal consequence	Legal aspects of NPS use
6	13	0.928	2017	Synthetic cannabinoid	Synthetic cannabinoids
8	8	0.984	2014	Rat urine	Metabolite profiles for drug screening
9	6	1.00	2013	Mapping project	NPS and the Internet
10	6	0.967	2015	Emerging epidemic	NPS as a New Public Health Problem

# 154 4. Discussion

In this section, we will discuss each cluster in greater detail in chronological order, by the average year of publication of the cluster. Each cluster will be analysed in terms of both the citing articles and the cited references. The main citing articles for each cluster will be highlighted, together with its coverage and Global Citing Score (GCS). Coverage refers to the number of articles in the cluster that were cited by the citing article and GCS refers to the total number of citations received by a paper as indexed on Scopus.

# 162 4.1. Cluster #5: Legal aspects of NPS

The major citing articles in Cluster #5 were authored by Bilinski et al. 163 [46] with a coverage of 14 articles and GCS of 6, and B McNabb et al. [47] 164 with a coverage of 11 articles and GCS of 11. Cluster #5 appears to be 165 one of the earlier groups of work investigating NPS emerging on the drug 166 market, their effects and their legal status, as seen from the mean year of 167 publication (2012) and a significant number of cited references conducted in 168 animal models prior to 2010 [48, 49, 50, 51, 52]. The primary theme of this 169 cluster appears to be legal concerns of NPS use following their entrance into 170 the market, where the citing articles focused on the legality of designer drugs 171 touted as "legal" in the drug market [46, 47]. Accordingly, there were also 172 cited references looking into the legal aspects of NPS use [53, 54]. 173

# 174 4.2. Cluster #1: Availability and use of NPS

The major citing articles in Cluster #1 were authored by Smith and 175 Garlich [55] with a coverage of 21 articles and GCS of 14, Wood and Dargan 176 [56] with a coverage of 16 articles and GCS of 7, and Wood and Dargan [57] 177 with a coverage of 14 articles and GCS of 54. Cluster #1 appears to be a 178 body of work that emerged in response to the series of bans on mephedrone 179 as well as other cathinones across multiple countries across the world in 180 2010, as evidenced by the mean year of publication (2012). The focus of 181 both citing articles and the cited references appeared to be the same, which 182 primarily revolved about the effects, prevalence and use of mephedrone and 183 other cathinones. A significant number of cited references examined their 184 use [38, 58, 59] and continued presence in the composition of existing drug 185 products available in the market [60, 35] despite their legal status, as well 186 as their effects (e.g. [61, 59, 62, 63]). This was also the case for many of 187 the citing articles which also looked at the effects of mephedrone and other 188 cathinones [57, 64, 56, 65]. 189

# 190 4.3. Cluster #9: NPS and the Internet

The major citing articles in Cluster #9 were authored by Deluca et al. [66] 191 with a coverage of 3 articles and GCS of 139, Cinosi et al. [67] with a coverage 192 of 2 articles and GCS of 99, and Corazza et al. [68] with a coverage of 2 articles 193 and GCS of 52. The main theme of Cluster #9 is the role of the Internet as 194 a source for information on NPS as well as a virtual marketplace for NPS. 195 It is clear from the cited articles that the availability of NPS through online 196 channels is a key concern, especially since consumer reach and engagement 197 on the Internet is unrivalled in comparison to a brick-and-mortar store, as 198 well as the information on NPS available on the Internet (e.g. [69, 70, 71, 190 72). Targeting the Internet through researching and designing web-based 200 interventions such as web monitoring and information dissemination is thus 201 a recommendation and/or central focus of the citing articles in Cluster #9202 (e.g. [66, 68]). Research in Cluster #9 highlights the information was on the 203 Internet as a key aspect of the NPS crisis and the importance of developing 204 information and communication technology interventions. 205

# 206 4.4. Cluster #8: Metabolite profiles for drug screening

The two major citing articles in Cluster #8 were authored by Welter et al. 207 [73] with a coverage of 8 articles and GCS of 25 and Welter et al. [74] with a 208 coverage of 72 articles and GCS of 6. Both of these citing articles investigated 209 methods for detecting of designer drugs through screening the metabolic 210 products present in rat urine by applying gas chromatography-mass spec-211 troscopy and/or liquid chromatography methods. This strongly suggests the 212 cluster is geared towards the application of these chemical methods to NPS 213 detection. Majority of the cited articles also report the results of applying 214 these methods to detect drug metabolites in urine (e.g. [75, 76, 77, 78, 79]). 215

## 216 4.5. Cluster #2: Neuropharmacology of NPS

The major citing articles in Cluster #2 were authored by Zawilska and 217 Andrzejczak [80] with a coverage of 10 articles and GCS of 120, Papaseit et al. 218 [81] with a coverage of 10 articles and GCS of 20, and [82] with a coverage 219 of 10 articles and GCS of 88, which were all reviews on the pharmacology 220 of NPS use. The cluster is centred in elucidating the pharmacology of the 221 various classes of NPS, which the citing articles covered from cathinones 222 (e.g. [83, 84]), cannabinoids (e.g. [85]), hallucinogens [86] and stimulants 223 [87]. The same theme is reflected in the cited articles, which were mostly 224 concerned with the toxicological findings from NPS use [33, 88, 43, 89, 90]. 225

Hence, Cluster #2 appears to be a body of work relating pharmacological
properties of NPS to their toxicity and risk of fatality.

## 228 4.6. Cluster #10: NPS as a New Public Health Problem

The major citing articles in Cluster #10 were authored by Zawilska and Andrzejczak [80] with a coverage of 4 articles and GCS of 36, Karila et al. [91] with a coverage of 3 articles and GCS of 129, and Rickli et al. [36] with a coverage of 3 articles and GCS of 129. The focus of these reviews aims to consolidate information on properties of NPS in relation to their propensity as a public health threat by presenting clinical data. The findings in the cited references also presents clinical data [92], including psychosis [93].

# 236 4.7. Cluster #3: Intoxication profile of NPS use

The major citing articles in Cluster #3 were authored by Schifano et al. 237 [94] with a coverage of 7 articles and GCS of 178. Salomone [95] with a cov-238 erage of 7 articles and GCS of 85, and Castaneto et al. [96] with a coverage 230 of 7 articles and GCS of 4, which were all reviews on the pharmacology of 240 NPS use. The cluster is composed of a group of work collecting data on 241 the intoxication profiles of NPS users (e.g. [97, 98, 99, 100, 101]). Notably, 242 a significant number of the citing articles analysed data from the STRIDA 243 project in Sweden, which monitored occurrences and health hazards of NPS 244 and includes information from about 2,600 cases of suspected NPS intoxica-245 tions across the period of 2010-2016 [102, 103, 104, 105, 106, 107]. Similarly, 246 the cited references were also research on intoxication profiles and fatality 247 from NPS use (e.g. [108, 109, 110, 111, 112, 113, 114, 115]). The size of the 248 cluster alludes to the public health threat that NPS use poses, as well as the 249 importance of the field of emergency medicine in monitoring adverse events 250 relating to drug use which can provide much needed data on the toxicological 251 and risk profile of NPS use. 252

#### 253 4.8. Cluster #6: Synthetic cannabinoids

The major citing articles in Cluster #6 were authored by Cannaert et al. [116] with a coverage of 5 articles and GCS of 22, Ametovski et al. [117] with a coverage of 5 articles and GCS of 5, and [118] with a coverage of 4 articles and GCS of 18. Considering that marijuana - which contains cannabis - is one of the most commonly use drugs in the world [119], it is not surprising that synthetic cannabinoids gained popularity as a "legal" alternative in countries - "Spice" being an example of a brand name cannabinoid drug

- where cannabis is controlled. Hence, this cluster of work examining the 261 effects of the recreational use of these synthetic cannabinoids appears to be in 262 response to their widespread use and market penetration in the recreational 263 drug market, especially considering its mean year of publication in 2017, 264 which was around the time period when cannabis began to be legalised for 265 recreational use and sale as a consumer product across a number of countries 266 such as Canada and the USA. The citing articles include research into the 267 pharamcology [120, 121, 122, 123], toxicology [124, 125, 126, 127] as well 268 as a number of articles pointing towards the sheer volume and continued 260 emergence of variations of synthetic cannabinoids [118, 128, 129]. Similarly, 270 a bulk of the cited references also focus mainly on synthetic cannabinoids 271 and their fatalities associated with their use [32, 130, 131, 132]. 272

# 273 4.9. Cluster #0: Mechanisms of NPS action

The major citing articles in Cluster #0 were authored by Miliano et al. 274 [82] with a coverage of 13 articles and GCS of 88, Rudin et al. [133] with a 275 coverage of 12 articles and GCS of 9, and Ellefsen et al. [83] with a coverage 276 of 11 articles and GCS of 45, which were all reviews on the pharmacologi-277 cal effects of NPS use. Firstly, many of the cited references in the cluster 278 discussed fatalities from NPS use (e.g. [31, 39, 134, 135]), indicating that 279 research on NPS is driven towards characterising the risk profile of NPS use 280 in terms of clinical outcomes and fatalities. Secondly, each of the major 281 citing articles were focused on different classes of NPS; Miliano et al. [82] 282 focused on cannabimimetics and amphetamine stimulants, Rudin et al. [133] 283 on stimulant and psychedelic NPS and Ellefsen et al. [83] on synthetic cathi-284 nones. This highlights the diversity of NPS classes available, which poses 285 an immense challenge to the scientific community as evidenced by the con-286 stant refrain of a lack of understanding of these mechanisms in many citing 287 articles. A tremendous effort is required in organising and conducting re-288 search into understanding the drug action and effects of the different classes 289 of NPS, as seen from the size of this cluster. A defining characteristic of the 290 NPS phenomenon, the rapid development of NPS entering the drug market 291 suggests the continual need for research to update the scientific understand-292 ing of the mechanisms of drug action, which is suggested by the relatively 293 recent mean year of publication (2019). Many of the references being cited 294 were also investigating the pharmacological actions and toxicity of NPS (e.g. 295 [36, 41, 136, 137, 138, 139]), further highlighting the need to constantly build 296

<sup>297</sup> onto existing scientific knowledge because of the sheer speed of NPS varia-<sup>298</sup> tions being introduced in the market.

# 299 4.10. Cluster #4: New synthetic opioids

The major citing articles in Cluster #4 were authored by Vandeputte 300 et al. [140] with a coverage of 7 articles and GCS of 1, Vandeputte et al. 301 [141] with a coverage of 7 articles and GCS of 3, and [142] with a coverage of 302 7 articles and GCS of 10. Given its recent mean year of publication (2020), 303 the cluster is very likely to be a group of work in response to rising use of 304 synthetic opioids globally. While the opioid crisis is not a new phenomenon, a 305 spotlight has been thrown onto synthetic opioid use in the wake of the recent 306 surge in opioid overdose deaths in the US - an opioid overdose epidemic driven 307 by synthetic opioids, fentanyl and its derivatives in particular [143, 144, 145]. 308 The cited reference with the highest burst strengths in this cluster focuses 309 on fentanyl and other novel synthetic opioids [34, 146, 147], supporting this 310 notion. Many citing articles were concerned with opioid-related deaths [39, 311 148, 149, 150 and a significant number of articles pointed towards the rapidly 312 surging numbers globally and its implications on public health [151, 152, 153]. 313

# 314 4.11. Limitations

There are a number of limitations of the scientometric approach. The DCA is based on the quantity of citations and co-citation patterns in the retrieved references and does not provide a qualitative perspective for these citation patterns per se. Hence, the rationale for the cited references are not immediately clear from the scientometric analysis.

## 320 5. Conclusions

The NPS phenomenon is a major cause for concern in countries across 321 the globe and is a war on drugs fought on many fronts, as evidenced by the 322 diversity of scientific fields represented in the network of articles derived from 323 the DCA. Given the challenges that NPS pose in terms of drug monitoring, 324 surveillance, control and public health responses, understanding the scientific 325 literature and disciplines involved in research on NPS is a valuable contribu-326 tion to the field which can be harnessed in supporting drug policy and public 327 health response. Such an analysis can highlight the research gaps in NPS 328 to direct attention to and facilitating interdisciplinary research based on the 329 research domains and links identified. In addition, producers of NPS often 330

mine knowledge from scientific journals and an understanding of the information that is available can be useful in targeting and informing drug policy.
Thus, drug policy, monitoring and control can benefit from coordinated, interdisciplinary efforts to inform and develop a multi-pronged approach to the
NPS crisis in order to safeguard public health.

# 336 Conflict of interests

<sup>337</sup> The authors declare no conflict of interest.

# 338 References

- [1] U. N. O. on Drugs, Crime, Unodc early warning advisory on new psychoactive substances, 2021. URL: https://www.unodc.org/LSS/
   Page/NPS.
- [2] C. Soussan, A. Kjellgren, The users of novel psychoactive substances:
  online survey about their characteristics, attitudes and motivations,
  International Journal of Drug Policy 32 (2016) 77–84.
- [3] A. Batisse, C. Eiden, H. Peyriere, S. Djezzar, et al., Use of new psychoactive substances to mimic prescription drugs: The trend in france,
  Neurotoxicology 79 (2020) 20-24.
- [4] C. D. Smith, S. Robert, 'designer drugs': update on the management of
   novel psychoactive substance misuse in the acute care setting, Clinical
   medicine 14 (2014) 409.
- [5] C. D. Smith, M. Williams, M. Shaikh, Novel psychoactive substances: a novel clinical challenge, Case Reports 2013 (2013) bcr2013200663.
- [6] N. Scherbaum, F. Schifano, U. Bonnet, New psychoactive substances
   (nps)-a challenge for the addiction treatment services, Pharmacopsychiatry 50 (2017) 116-122.
- P. O. of the European Union, M. Evans-Brown, A. Gallegos, W. Francis, R. Christie, A. Cunningham, J. Sekula, A. Almeida, R. Sedefov, Publications Office, 2015.
- [8] M. Evans-Brown, R. Sedefov, New psychoactive substances: driving
   greater complexity into the drug problem, Addiction 112 (2017) 36–38.

- [9] A. Peacock, R. Bruno, N. Gisev, L. Degenhardt, W. Hall, R. Sedefov,
  J. White, K. V. Thomas, M. Farrell, P. Griffiths, New psychoactive substances: challenges for drug surveillance, control, and public health responses, The Lancet 394 (2019) 1668–1684.
- [10] L. Kraus, A. Nociar, ESPAD report 2015: results from the European
   school survey project on alcohol and other drugs, European Monitoring
   Centre for Drugs and Drug Addiction, 2016.
- [11] C. Chen, The citespace manual, College of Computing and Informatics
   1 (2014) 1–84.
- [12] C. Chen, F. Ibekwe-SanJuan, J. Hou, The structure and dynamics of cocitation clusters: A multiple-perspective cocitation analysis, Journal of the American Society for information Science and Technology 61 (2010) 1386–1409.
- [13] A. Carollo, J. P. M. Balagtas, M. J.-Y. Neoh, G. Esposito, A scientometric approach to review the role of the medial preoptic area (mpoa)
  in parental behavior, Brain Sciences 11 (2021) 393.
- I. Cataldo, A. A. Lieu, A. Carollo, M. H. Bornstein, G. Gabrieli, A. Lee,
  G. Esposito, From the cradle to the web: The growth of "sharenting"—a scientometric perspective, Human Behavior and Emerging Technologies 2022 (2022).
- [15] A. Carollo, A. Bonassi, M. Lim, G. Gabrieli, P. Setoh, D. Dimitriou,
   V. Aryadoust, G. Esposito, Developmental disabilities across the world:
   A scientometric review from 1936 to 2020, Research in Developmental
   Disabilities 117 (2021) 104031.
- [16] C. Chen, CiteSpace: a practical guide for mapping scientific literature,
   Nova Science Publishers Hauppauge, NY, USA, 2016.
- [17] H. Small, Co-citation context analysis and the structure of paradigms,
   Journal of documentation (1980).
- [18] A. Carollo, M. Lim, V. Aryadoust, G. Esposito, Interpersonal syn chrony in the context of caregiver-child interactions: a document co citation analysis, Frontiers in Psychology (2021) 2977.

- [19] A. Carollo, S. Fong, G. Gabrieli, C. Mulatti, G. Esposito, To wine or
  not to wine? a scientometric approach to 65+ years of wine preference
  and selection studies, British Food Journal (2022).
- [20] M. Lim, A. Carollo, D. Dimitriou, G. Esposito, Recent developments
   in autism genetic research: A scientometric review from 2018 to 2022,
   Genes 13 (2022) 1646.
- <sup>398</sup> [21] L. Egghe, Theory and practise of the g-index, Scientometrics 69 (2006) <sup>399</sup> 131–152.
- [22] S. Alonso, F. J. Cabrerizo, E. Herrera-Viedma, F. Herrera, h-index:
  A review focused in its variants, computation and standardization for
  different scientific fields, Journal of informetrics 3 (2009) 273–289.
- [23] M. E. Newman, Modularity and community structure in networks,
   Proceedings of the national academy of sciences 103 (2006) 8577–8582.
- [24] P. J. Rousseeuw, Silhouettes: a graphical aid to the interpretation and
  validation of cluster analysis, Journal of computational and applied
  mathematics 20 (1987) 53-65.
- <sup>408</sup> [25] V. Aryadoust, B. H. Ang, Exploring the frontiers of eye tracking re<sup>409</sup> search in language studies: a novel co-citation scientometric review,
  <sup>410</sup> Computer Assisted Language Learning 34 (2021) 898–933.
- [26] L. C. Freeman, A set of measures of centrality based on betweenness,
   Sociometry (1977) 35–41.
- [27] V. Aryadoust, H. A. H. Tan, L. Y. Ng, A scientometric review of
  rasch measurement: The rise and progress of a specialty, Frontiers in
  psychology (2019) 2197.
- [28] J. Kleinberg, Bursty and hierarchical structure in streams, Data mining
  and knowledge discovery 7 (2003) 373–397.
- <sup>418</sup> [29] C. Chen, Science mapping: a systematic review of the literature, Jour-<sup>419</sup> nal of data and information science 2 (2017) 1–40.
- [30] C. Chen, Y. Chen, M. Horowitz, H. Hou, Z. Liu, D. Pellegrino, Towards an explanatory and computational theory of scientific discovery,
  Journal of Informetrics 3 (2009) 191–209.

- [31] L. Hondebrink, J. J. Nugteren-van Lonkhuyzen, D. Van Der Gouwe,
  T. M. Brunt, Monitoring new psychoactive substances (nps) in the
  netherlands: data from the drug market and the poisons information
  centre, Drug and alcohol dependence 147 (2015) 109–115.
- [32] M. S. Castaneto, D. A. Gorelick, N. A. Desrosiers, R. L. Hartman,
  S. Pirard, M. A. Huestis, Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications, Drug and alcohol dependence
  144 (2014) 12–41.
- [33] M. Hermanns-Clausen, S. Kneisel, B. Szabo, V. Auwärter, Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings, Addiction 108 (2013) 534–544.
- [34] P. Armenian, K. T. Vo, J. Barr-Walker, K. L. Lynch, Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review,
  Neuropharmacology 134 (2018) 121–132.
- [35] S. D. Brandt, L. A. King, M. Evans-Brown, The new drug phenomenon,
   2014.
- [36] A. Rickli, M. C. Hoener, M. E. Liechti, Monoamine transporter and
  receptor interaction profiles of novel psychoactive substances: parahalogenated amphetamines and pyrovalerone cathinones, European
  Neuropsychopharmacology 25 (2015) 365–376.
- [37] H. Morris, J. Wallach, From pcp to mxe: a comprehensive review of
  the non-medical use of dissociative drugs, Drug testing and analysis 6
  (2014) 614–632.
- [38] F. Measham, D. M. Wood, P. I. Dargan, K. Moore, The rise in legal
  highs: prevalence and patterns in the use of illegal drugs and firstand second-generation "legal highs" in south london gay dance clubs,
  Journal of Substance Use 16 (2011) 263–272.
- [39] M. Kraemer, A. Boehmer, B. Madea, A. Maas, Death cases involving certain new psychoactive substances: a review of the literature,
  Forensic science international 298 (2019) 186–267.

- [40] K. A. Seely, J. Lapoint, J. H. Moran, L. Fattore, Spice drugs are more
  than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids, Progress in Neuro-psychopharmacology
  and biological psychiatry 39 (2012) 234–243.
- [41] L. H. Richter, H. H. Maurer, M. R. Meyer, New psychoactive substances: studies on the metabolism of xlr-11, ab-pinaca, fub-pb-22,
  459 4-methoxy-α-pvp, 25-i-nbome, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine, Toxicology Letters 280 (2017) 142–150.
- [42] M. H. Baumann, M. A. Ayestas, J. S. Partilla, J. R. Sink, A. T.
  Shulgin, P. F. Daley, S. D. Brandt, R. B. Rothman, A. E. Ruoho,
  N. V. Cozzi, The designer methcathinone analogs, mephedrone and
  methylone, are substrates for monoamine transporters in brain tissue,
  Neuropsychopharmacology 37 (2012) 1192–1203.
- <sup>467</sup> [43] J. M. Prosser, L. S. Nelson, The toxicology of bath salts: a review of <sup>468</sup> synthetic cathinones, Journal of Medical Toxicology 8 (2012) 33–42.
- [44] M. Majchrzak, R. Celiński, P. Kuś, T. Kowalska, M. Sajewicz, The
  newest cathinone derivatives as designer drugs: an analytical and toxicological review, Forensic toxicology 36 (2018) 33–50.
- [45] D. Favretto, J. P. Pascali, F. Tagliaro, New challenges and innovation
  in forensic toxicology: focus on the "new psychoactive substances",
  Journal of chromatography A 1287 (2013) 84–95.
- [46] P. Bilinski, P. Holownia, L. Kapka-Skrzypczak, A. Wojtyla, Designer
  drug (dd) abuse in poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the
  legal consequences thereof. part ii-piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous 'others', Annals of Agricultural
  and Environmental Medicine 19 (2012).
- [47] C. B McNabb, B. R Russell, D. Caprioli, D. J Nutt, S. Gibbons,
  J. W Dalley, Single chemical entity legal highs: assessing the risk
  for long term harm, Current Drug Abuse Reviews 5 (2012) 304–319.

- [48] R. Nonaka, F. Nagai, A. Ogata, K. Satoh, In vitro screening of psychoactive drugs by [35s] gtpγs binding in rat brain membranes, Biological and Pharmaceutical Bulletin 30 (2007) 2328–2333.
- [49] F. Nagai, R. Nonaka, K. S. H. Kamimura, The effects of non-medically
   used psychoactive drugs on monoamine neurotransmission in rat brain,
   European journal of pharmacology 559 (2007) 132–137.
- <sup>490</sup> [50] W. E. Fantegrossi, G. Winger, J. Woods, W. Woolverton, A. Coop, Re<sup>491</sup> inforcing and discriminative stimulus effects of 1-benzylpiperazine and
  <sup>492</sup> trifluoromethylphenylpiperazine in rhesus monkeys, Drug and alcohol
  <sup>493</sup> dependence 77 (2005) 161–168.
- [51] K. M. Wilcox, H. L. Kimmel, K. P. Lindsey, J. R. Votaw, M. M. Goodman, L. L. Howell, In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys, Synapse 58 (2005) 220–228.
- [52] M. H. Baumann, R. D. Clark, A. G. Budzynski, J. S. Partilla, B. E.
  Blough, R. B. Rothman, Effects of "legal x" piperazine analogs on dopamine and serotonin release in rat brain, Annals of the New York Academy of Sciences 1025 (2004) 189–197.
- [53] S. Davies, D. M. Wood, G. Smith, J. Button, J. Ramsey, R. Archer,
  D. W. Holt, P. I. Dargan, Purchasing 'legal highs' on the internet—is
  there consistency in what you get?, QJM: An International Journal of
  Medicine 103 (2010) 489–493.
- L. Kapka-Skrzypczak, P. Kulpa, K. Sawicki, M. Cyranka, A. Wojtyla,
   M. Kruszewski, Legal highs-legal aspects and legislative solutions, Annals of Agricultural and Environmental Medicine 18 (2011).
- [55] S. W. Smith, F. M. Garlich, Availability and supply of novel psychoactive substances, in: Novel psychoactive substances, Elsevier, 2013, pp.
  55–77.
- <sup>512</sup> [56] D. M. Wood, P. I. Dargan, Mephedrone, in: Novel psychoactive sub-<sup>513</sup> stances, Elsevier, 2013, pp. 211–231.

- [57] D. M. Wood, P. I. Dargan, Novel psychoactive substances: how to un derstand the acute toxicity associated with the use of these substances,
   Therapeutic drug monitoring 34 (2012) 363–367.
- [58] D. Wood, L. Hunter, F. Measham, P. Dargan, Limited use of novel
  psychoactive substances in south london nightclubs, QJM: An international journal of medicine 105 (2012) 959–964.
- [59] P. Dargan, S. Albert, D. Wood, Mephedrone use and associated adverse effects in school and college/university students before the uk
  legislation change, QJM: An International Journal of Medicine 103 (2010) 875–879.
- [60] J. Ramsey, P. Dargan, M. Smyllie, S. Davies, J. Button, D. Holt,
  D. Wood, Buying 'legal'recreational drugs does not mean that you are not breaking the law, QJM: An International Journal of Medicine
  103 (2010) 777-783.
- [61] D. M. Wood, S. Davies, M. Puchnarewicz, J. Button, R. Archer,
  H. Ovaska, J. Ramsey, T. Lee, D. W. Holt, P. I. Dargan, Recreational
  use of mephedrone (4-methylmethcathinone, 4-mmc) with associated
  sympathomimetic toxicity, Journal of Medical Toxicology 6 (2010)
  327–330.
- [62] D. Wood, S. Greene, P. Dargan, Clinical pattern of toxicity associated
   with the novel synthetic cathinone mephedrone, Emergency medicine
   journal 28 (2011) 280–282.
- [63] P. I. Dargan, R. Sedefov, A. Gallegos, D. M. Wood, The pharmacology and toxicology of the synthetic cathinone mephedrone (4methylmethcathinone), Drug testing and analysis 3 (2011) 454–463.
- [64] D. Wood, P. Dargan, Understanding how data triangulation identifies
   acute toxicity of novel psychoactive drugs, Journal of Medical Toxicol ogy 8 (2012) 300–303.
- [65] B. Loi, J. M. Corkery, H. Claridge, C. Goodair, S. Chiappini, C. Gimeno Clemente, F. Schifano, Deaths of individuals aged 16–24 years in
  the uk after using mephedrone, Human Psychopharmacology: Clinical
  and Experimental 30 (2015) 225–232.

- [66] P. Deluca, Z. Davey, O. Corazza, L. Di Furia, M. Farre, L. H. Flesland,
  M. Mannonen, A. Majava, T. Peltoniemi, M. Pasinetti, et al., Identifying emerging trends in recreational drug use; outcomes from the psychonaut web mapping project, Progress in Neuro-Psychopharmacology
  and Biological Psychiatry 39 (2012) 221–226.
- [67] E. Cinosi, G. Martinotti, P. Simonato, D. Singh, Z. Demetrovics,
  A. Roman-Urrestarazu, F. S. Bersani, B. Vicknasingam, G. Piazzon,
  J.-H. Li, et al., Following "the roots" of kratom (mitragyna speciosa):
  the evolution of an enhancer from a traditional use to increase work
  and productivity in southeast asia to a recreational psychoactive drug
  in western countries, BioMed research international 2015 (2015).
- [68] O. Corazza, G. Valeriani, F. S. Bersani, J. Corkery, G. Martinotti,
  G. Bersani, F. Schifano, "spice," "kryptonite," "black mamba": an
  overview of brand names and marketing strategies of novel psychoactive substances on the web, Journal of Psychoactive Drugs 46 (2014)
  287–294.
- [69] O. Corazza, S. Assi, P. Simonato, J. Corkery, F. S. Bersani, Z. Demetrovics, J. Stair, S. Fergus, C. Pezzolesi, M. Pasinetti, et al., Promoting
  innovation and excellence to face the rapid diffusion of novel psychoactive substances in the eu: the outcomes of the rednet project, Human
  Psychopharmacology: Clinical and Experimental 28 (2013) 317–323.
- [70] F. Schifano, O. Corazza, P. Deluca, Z. Davey, L. Di Furia, M. Farre',
  L. Flesland, M. Mannonen, S. Pagani, T. Peltoniemi, et al., Psychoactive drug or mystical incense? overview of the online available
  information on spice products, International Journal of Culture and
  Mental Health 2 (2009) 137–144.
- [71] O. Corazza, F. Schifano, P. Simonato, S. Fergus, S. Assi, J. Stair,
  J. Corkery, G. Trincas, P. Deluca, Z. Davey, et al., Phenomenon of
  new drugs on the internet: the case of ketamine derivative methoxetamine, Human Psychopharmacology: Clinical and Experimental 27
  (2012) 145–149.
- F. Schifano, P. Deluca, L. Agosti, G. Martinotti, J. M. Corkery, P. . R.
   Group, New trends in the cyber and street market of recreational

drugs? the case of 2c-t-7 ('blue mystic'), Journal of Psychopharmacology 19 (2005) 675–679.

- [73] J. Welter, M. R. Meyer, P. Kavanagh, H. H. Maurer, Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using gc-ms and lc-(high-resolution)-ms n, Analytical and bioanalytical chemistry 406 (2014) 1957–1974.
- J. Welter, P. Kavanagh, H. H. Maurer, Gc-ms and lc-(high-resolution)ms n studies on the metabolic fate and detectability of camfetamine
  in rat urine, Analytical and bioanalytical chemistry 406 (2014) 3815–
  3829.
- [75] M. R. Meyer, F. T. Peters, H. H. Maurer, Automated mass spectral deconvolution and identification system for gc-ms screening for drugs, poisons, and metabolites in urine, Clinical chemistry 56 (2010) 575–584.
- [76] A. H. Ewald, D. Ehlers, H. H. Maurer, Metabolism and toxicological
   detection of the designer drug 4-chloro-2, 5-dimethoxyamphetamine in
   rat urine using gas chromatography-mass spectrometry, Analytical and
   bioanalytical chemistry 390 (2008) 1837–1842.
- [77] M. R. Meyer, M. Bach, J. Welter, M. Bovens, A. Turcant, H. H. Maurer, Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using gc-ms and lc-(hr-) ms n, Analytical and bioanalytical chemistry 405 (2013) 6307– 602 6321.
- [78] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Weber, H. H.
  Maurer, Development of the first metabolite-based lc-ms n urine drug
  screening procedure-exemplified for antidepressants, Analytical and
  bioanalytical chemistry 400 (2011) 79–88.
- [79] D. K. Wissenbach, M. R. Meyer, D. Remane, A. A. Philipp, A. A.
  Weber, H. H. Maurer, Drugs of abuse screening in urine as part of a
  metabolite-based lc-msn screening concept, Analytical and Bioanalytical Chemistry 400 (2011) 3481–3489.

- [80] J. B. Zawilska, D. Andrzejczak, Next generation of novel psychoactive substances on the horizon-a complex problem to face, Drug and
  Alcohol Dependence 157 (2015) 1–17.
- [81] E. Papaseit, J. Moltó, R. Muga, M. Torrens, R. d. l. Torre, M. Farré,
  Clinical pharmacology of the synthetic cathinone mephedrone, Neuropharmacology of New Psychoactive Substances (NPS) (2016) 313–
  331.
- [82] C. Miliano, G. Serpelloni, C. Rimondo, M. Mereu, M. Marti, M. A.
  De Luca, Neuropharmacology of new psychoactive substances (nps):
  focus on the rewarding and reinforcing properties of cannabimimetics
  and amphetamine-like stimulants, Frontiers in neuroscience 10 (2016)
  153.
- [83] K. N. Ellefsen, M. Concheiro, M. A. Huestis, Synthetic cathinone
  pharmacokinetics, analytical methods, and toxicological findings from
  human performance and postmortem cases, Drug metabolism reviews
  48 (2016) 237–265.
- [84] E. Papaseit, C. Pérez-Mañá, J.-A. Mateus, M. Pujadas, F. Fonseca,
  M. Torrens, E. Olesti, R. De La Torre, M. Farré, Human pharmacology
  of mephedrone in comparison with mdma, Neuropsychopharmacology
  41 (2016) 2704–2713.
- [85] C. Lovett, D. Wood, P. Dargan, Pharmacology and toxicology of the
  synthetic cannabinoid receptor agonists, Réanimation 24 (2015) 527–
  541.
- [86] C. Kyriakou, E. Marinelli, P. Frati, A. Santurro, M. Afxentiou, S. Zaami, F. P. Busardo, Nbome: new potent hallucinogens-pharmacology,
  analytical methods, toxicities, fatalities: a review, Eur Rev Med Pharmacol Sci 19 (2015) 3270-3281.
- [87] J. J. Nugteren-van Lonkhuyzen, A. J. van Riel, T. M. Brunt, L. Hondebrink, Pharmacokinetics, pharmacodynamics and toxicology of new
  psychoactive substances (nps): 2c-b, 4-fluoroamphetamine and benzofurans, Drug and alcohol dependence 157 (2015) 18–27.

- [88] M. Coppola, R. Mondola, 3, 4-methylenedioxypyrovalerone (mdpv):
  chemistry, pharmacology and toxicology of a new designer drug of abuse
  marketed online, Toxicology Letters 208 (2012) 12–15.
- [89] S. L. Hill, T. Doris, S. Gurung, S. Katebe, A. Lomas, M. Dunn,
  P. Blain, S. H. Thomas, Severe clinical toxicity associated with analytically confirmed recreational use of 25i-nbome: case series, Clinical
  Toxicology 51 (2013) 487-492.
- [90] D. James, R. D. Adams, R. Spears, G. Cooper, D. Lupton, J. P.
  Thompson, S. H. Thomas, Clinical characteristics of mephedrone toxicity reported to the uk national poisons information service, Emergency Medicine Journal 28 (2011) 686–689.
- [91] L. Karila, B. Megarbane, O. Cottencin, M. Lejoyeux, Synthetic cathinones: a new public health problem, Current neuropharmacology 13
  (2015) 12–20.
- [92] H. A. Spiller, M. L. Ryan, R. G. Weston, J. Jansen, Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the united states, Clinical toxicology 49 (2011) 499–505.
- [93] D. Papanti, F. Schifano, G. Botteon, F. Bertossi, J. Mannix, D. Vidoni,
  M. Impagnatiello, E. Pascolo-Fabrici, T. Bonavigo, "spiceophrenia": a
  systematic overview of "spice"-related psychopathological issues and a
  case report, Human Psychopharmacology: Clinical and Experimental
  28 (2013) 379–389.
- [94] F. Schifano, L. Orsolini, G. Duccio Papanti, J. M. Corkery, Novel
   psychoactive substances of interest for psychiatry, World Psychiatry
   14 (2015) 15–26.
- [95] A. Salomone, Detection of new psychoactive substances, in: Hair
   Analysis in Clinical and Forensic Toxicology, Elsevier, 2015, pp. 301–
   336.
- [96] M. S. Castaneto, A. Wohlfarth, N. A. Desrosiers, R. L. Hartman, D. A.
  Gorelick, M. A. Huestis, Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices, Drug metabolism reviews 47 (2015) 124–174.

- [97] R. Kronstrand, D. Guerrieri, S. Vikingsson, A. Wohlfarth, H. Gréen,
  Fatal poisonings associated with new psychoactive substances, in: New
  psychoactive substances, Springer, 2018, pp. 495–541.
- [98] S. L. Hill, P. I. Dargan, Patterns of acute toxicity associated with new psychoactive substances, in: New Psychoactive Substances, Springer, 2018, pp. 475–494.
- [99] L. Ventura, F. Carvalho, R. J. Dinis-Oliveira, Opioids in the frame of
   new psychoactive substances network: a complex pharmacological and
   toxicological issue, Current Molecular Pharmacology 11 (2018) 97–108.
- [100] M. H. Tang, Y. Chong, C. Y. Chan, C. Ching, C. Lai, Y. Li, T. W.
   Mak, Cluster of acute poisonings associated with an emerging ketamine analogue, 2-oxo-pce, Forensic science international 290 (2018) 238–243.
- [101] C. R. Caffrey, P. M. Lank, When good times go bad: managing 'legal
   high'complications in the emergency department, Open access emergency medicine: OAEM 10 (2018) 9.
- [102] M. Bäckberg, O. Beck, A. Helander, Phencyclidine analog use in swe den—intoxication cases involving 3-meo-pcp and 4-meo-pcp from the
   strida project, Clinical Toxicology 53 (2015) 856–864.
- [103] M. Bäckberg, O. Beck, K.-H. Jönsson, A. Helander, Opioid intoxica tions involving butyrfentanyl, 4-fluorobutyrfentanyl, and fentanyl from
   the swedish strida project, Clinical Toxicology 53 (2015) 609–617.
- [104] A. Helander, O. Beck, M. Bäckberg, Intoxications by the dissociative
   new psychoactive substances diphenidine and methoxphenidine, Clin ical toxicology 53 (2015) 446–453.
- [105] A. Helander, M. Bäckberg, Epidemiology of nps based confirmed overdose cases: the strida project, in: New Psychoactive Substances,
  Springer, 2018, pp. 461–473.
- [106] M. Bäckberg, K.-H. Jönsson, O. Beck, A. Helander, Investigation of
   drug products received for analysis in the swedish strida project on new
   psychoactive substances, Drug testing and analysis 10 (2018) 340–349.

- [107] O. Beck, L. Franzen, M. Bäckberg, P. Signell, A. Helander, Intoxications involving mdpv in sweden during 2010–2014: results from the
  strida project, Clinical toxicology 53 (2015) 865–873.
- [108] K. Miotto, J. Striebel, A. K. Cho, C. Wang, Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports,
  Drug and alcohol dependence 132 (2013) 1–12.
- [109] I. M. McIntyre, R. D. Gary, S. Joseph, R. Stabley, A fatality related to
  the synthetic opioid u-47700: postmortem concentration distribution,
  Journal of Analytical Toxicology 41 (2017) 158–160.
- [110] A. Helander, M. Bäckberg, O. Beck, Intoxications involving the fentanyl analogs acetylfentanyl, 4-methoxybutyrfentanyl and furanylfentanyl: results from the swedish strida project, Clinical Toxicology 54 (2016) 324–332.
- [111] M. Bäckberg, L. Tworek, O. Beck, A. Helander, Analytically confirmed intoxications involving mdmb-chmica from the strida project, Journal of medical toxicology 13 (2017) 52–60.
- [112] B. K. Logan, A. L. Mohr, M. Friscia, A. J. Krotulski, D. M. Papsun,
  S. L. Kacinko, J. D. Ropero-Miller, M. A. Huestis, Reports of adverse
  events associated with use of novel psychoactive substances, 2013–2016:
  a review, Journal of Analytical Toxicology 41 (2017) 573–610.
- [113] P. Adamowicz, D. Zuba, Fatal intoxication with methoxetamine, Jour nal of Forensic Sciences 60 (2015) S264–S268.
- [114] M. Bäckberg, O. Beck, P. Hulten, J. Rosengren-Holmberg, A. Helander,
  Intoxications of the new psychoactive substance 5-(2-aminopropyl) indole (5-it): a case series from the swedish strida project, Clinical
  toxicology 52 (2014) 618–624.
- [115] R. Kronstrand, G. Thelander, D. Lindstedt, M. Roman, F. Kugelberg,
   Fatal intoxications associated with the designer opioid ah-7921, Journal
   of analytical toxicology 38 (2014) 599–604.
- [116] A. Cannaert, E. Sparkes, E. Pike, J. L. Luo, A. Fang, R. C. Kevin,
  R. Ellison, R. Gerona, S. D. Banister, C. P. Stove, Synthesis and

in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids 4f-mdmb-bica, 5f-mpp-pica, mmb-4en-pica, cumylcbmica, adb-binaca, app-binaca, 4f-mdmb-binaca, mdmb-4en-pinaca,
a-chminaca, 5f-ab-p7aica, 5f-mdmb-p7aica, and 5f-ap7aica, ACS
Chemical Neuroscience 11 (2020) 4434-4446.

- [117] A. Ametovski, C. Macdonald, J. J. Manning, S. S. Haneef, M. Santiago, L. Martin, E. Sparkes, A. Reckers, R. R. Gerona, M. Connor,
  et al., Exploring stereochemical and conformational requirements at
  cannabinoid receptors for synthetic cannabinoids related to sdb-006, 5fsdb-006, cumyl-pica, and 5f-cumyl-pica, ACS Chemical Neuroscience
  11 (2020) 3672–3682.
- [118] V. Shevyrin, V. Melkozerov, G. W. Endres, Y. Shafran, Y. Morzherin,
  On a new cannabinoid classification system: a sight on the illegal market of novel psychoactive substances, Cannabis and Cannabinoid Research 1 (2016) 186–194.
- [119] N. I. o. D. A. N. I. o. H. U. D. o. H. , H. Services, Cannabis (marijuana) drugfacts, 2022. URL: https://nida.nih.gov/publications/ drugfacts/cannabis-marijuana#ref.
- [120] E. Y. Chung, H. J. Cha, H. K. Min, J. Yun, Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists, Archives of Pharmacal Research 44 (2021) 402–413.
- [121] S. Sachdev, S. D. Banister, M. Santiago, C. Bladen, M. Kassiou,
   M. Connor, Differential activation of g protein-mediated signaling by
   synthetic cannabinoid receptor agonists, Pharmacology research & per spectives 8 (2020) e00566.
- [122] M. Patel, J. J. Manning, D. B. Finlay, J. A. Javitch, S. D. Banister,
  N. L. Grimsey, M. Glass, Signalling profiles of a structurally diverse
  panel of synthetic cannabinoid receptor agonists, Biochemical Pharmacology 175 (2020) 113871.
- [123] Z. Hassan, O. G. Bosch, D. Singh, S. Narayanan, B. V. Kasinather,
  E. Seifritz, J. Kornhuber, B. B. Quednow, C. P. Müller, Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs, Frontiers in psychiatry 8 (2017)
  152.

- [124] H. Chung, J. Lee, E. Kim, Trends of novel psychoactive substances
  (npss) and their fatal cases, Forensic Toxicology 34 (2016) 1–11.
- [125] V. L. Alves, J. L. Gonçalves, J. Aguiar, H. M. Teixeira, J. S. Câmara,
  The synthetic cannabinoids phenomenon: from structure to toxicological properties. a review, Critical Reviews in Toxicology 50 (2020)
  359–382.
- [126] A. Giorgetti, F. P. Busardò, R. Tittarelli, V. Auwärter, R. Giorgetti,
  Post-mortem toxicology: a systematic review of death cases involving
  synthetic cannabinoid receptor agonists, Frontiers in Psychiatry 11
  (2020) 464.
- [127] T. Coccini, U. De Simone, D. Lonati, G. Scaravaggi, M. Marti, C. Locatelli, Mam-2201, one of the most potent—naphthoyl indole derivative—synthetic cannabinoids, exerts toxic effects on human cell-based
  models of neurons and astrocytes, Neurotoxicity Research 39 (2021)
  1251–1273.
- [128] M. Valento, J. Lebin, Emerging drugs of abuse: synthetic cannabinoids,
  phenylethylamines (2c drugs), and synthetic cathinones, Clinical Pediatric Emergency Medicine 18 (2017) 203-211.
- [129] R. Kikura-Hanajiri, New designer drugs in japan, in: Neuropathology
   of drug addictions and substance misuse, Elsevier, 2016, pp. 1055–1065.
- [130] J. Trecki, R. R. Gerona, M. D. Schwartz, et al., Synthetic cannabinoid related illnesses and deaths, N Engl J Med 373 (2015) 103–107.
- [131] S. D. Banister, M. Longworth, R. Kevin, S. Sachdev, M. Santiago,
  J. Stuart, J. B. Mack, M. Glass, I. S. McGregor, M. Connor, et al.,
  Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5fambica, 5f-amb, 5f-adb, amb-fubinaca, mdmb-fubinaca, mdmb-chmica,
  and their analogues, ACS Chemical Neuroscience 7 (2016) 1241–1254.
- [132] C. Hess, C. T. Schoeder, T. Pillaiyar, B. Madea, C. E. Müller, Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice, Forensic toxicology 34 (2016) 329–343.

- [133] D. Rudin, M. E. Liechti, D. Luethi, Molecular and clinical aspects
   of potential neurotoxicity induced by new psychoactive stimulants and
   psychedelics, Experimental neurology 343 (2021) 113778.
- <sup>803</sup> [134] S. Elliott, J. Evans, A 3-year review of new psychoactive substances in <sup>804</sup> casework, Forensic science international 243 (2014) 55–60.
- [135] S. Zaami, R. Giorgetti, S. Pichini, F. Pantano, E. Marinelli, F. Busardò,
  Synthetic cathinones related fatalities: an update, Eur Rev Med Pharmacol Sci 22 (2018) 268–274.
- [136] L. Hondebrink, A. Zwartsen, R. H. Westerink, Effect fingerprinting of
  new psychoactive substances (nps): What can we learn from in vitro
  data?, Pharmacology & therapeutics 182 (2018) 193–224.
- [137] A. Rickli, D. Luethi, J. Reinisch, D. Buchy, M. C. Hoener, M. E.
  Liechti, Receptor interaction profiles of novel n-2-methoxybenzyl
  (nbome) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2c
  drugs), Neuropharmacology 99 (2015) 546-553.
- [138] A. J. Eshleman, K. M. Wolfrum, J. F. Reed, S. O. Kim, R. A. Johnson,
  A. Janowsky, Neurochemical pharmacology of psychoactive substituted
  n-benzylphenethylamines: High potency agonists at 5-ht2a receptors,
  Biochemical pharmacology 158 (2018) 27–34.
- [139] L. Simmler, A. Rickli, M. Hoener, M. Liechti, Monoamine transporter
  and receptor interaction profiles of a new series of designer cathinones,
  Neuropharmacology 79 (2014) 152–160.
- [140] M. M. Vandeputte, N. Verougstraete, D. Walther, G. C. Glatfelter,
  J. Malfliet, M. H. Baumann, A. G. Verstraete, C. P. Stove, First
  identification, chemical analysis and pharmacological characterization
  of n-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2benzylbenzimidazole opioid subclass, Archives of Toxicology 96 (2022)
  1865–1880.
- [141] M. M. Vandeputte, M. Persson, D. Walther, S. Vikingsson, R. Kronstrand, M. H. Baumann, H. Gréen, C. P. Stove, Characterization of recent non-fentanyl synthetic opioids via three different in vitro  $\mu$ opioid receptor activation assays, Archives of Toxicology 96 (2022) 877–897.

- [142] S. Salle, S. Bodeau, A. Dhersin, M. Ferdonnet, R. Goncalves,
  M. Lenski, B. Lima, M. Martin, J. Outreville, J. Vaucel, et al., Novel
  synthetic opioids: A review of the literature, Toxicologie Analytique
  et Clinique 31 (2019) 298–316.
- [143] N. C. f. H. S. CDC, U.s. overdose deaths in 2021 increased half as much as in 2020 - but are still up 15%, 2022. URL: https://www.cdc.gov/ nchs/pressroom/nchs\_press\_releases/2022/202205.htm.
- [144] C. for Disease Control, Prevention, Understanding the epidemic, 2021.
   URL: https://www.cdc.gov/drugoverdose/epidemic/index.html.
- [145] C. L. Mattson, L. J. Tanz, K. Quinn, M. Kariisa, P. Patel, N. L. Davis,
  Trends and geographic patterns in drug and synthetic opioid overdose
  deaths—united states, 2013–2019, Morbidity and Mortality Weekly
  Report 70 (2021) 202.
- <sup>846</sup> [146] M. P. Prekupec, P. A. Mansky, M. H. Baumann, Misuse of novel
  <sup>847</sup> synthetic opioids: a deadly new trend, Journal of addiction medicine
  <sup>848</sup> 11 (2017) 256.
- [147] M. H. Baumann, S. Majumdar, V. Le Rouzic, A. Hunkele, R. Uprety,
  X. P. Huang, J. Xu, B. L. Roth, Y.-X. Pan, G. W. Pasternak, Pharmacological characterization of novel synthetic opioids (nso) found in the recreational drug marketplace, Neuropharmacology 134 (2018) 101– 107.
- [148] I. Tabarra, S. Soares, T. Rosado, J. Gonçalves, A. Luís, S. Malaca,
  M. Barroso, T. Keller, J. Restolho, E. Gallardo, Novel synthetic
  opioids-toxicological aspects and analysis, Forensic Sciences Research
  4 (2019) 111–140.
- [149] N. Allibe, F. Billault, C. Moreau, A. Marchard, Y. Gaillard, G. Hoizey,
  H. Eysseric-Guerin, N. Milan, Ocfentanil in france: seven case reports
  (2016–2018), Toxicologie Analytique et Clinique 31 (2019) 317–322.
- [150] S. Darke, A. Peacock, J. Duflou, M. Farrell, J. Lappin, Characteristics
   of fatal 'novel'synthetic opioid toxicity in australia, Drug and alcohol
   dependence 232 (2022) 109292.

- [151] L. Karila, M. Marillier, B. Chaumette, J. Billieux, N. Franchitto,
  A. Benyamina, New synthetic opioids: Part of a new addiction landscape, Neuroscience & Biobehavioral Reviews 106 (2019) 133–140.
- [152] B. Lovrecic, M. Lovrecic, B. Gabrovec, M. Carli, M. Pacini, A. G.
  Maremmani, I. Maremmani, Non-medical use of novel synthetic opioids: a new challenge to public health, International journal of environmental research and public health 16 (2019) 177.
- [153] A. Y. Simão, M. Antunes, E. Cabral, P. Oliveira, L. M. Rosendo, A. T.
  Brinca, E. Alves, H. Marques, T. Rosado, L. A. Passarinha, et al.,
  An update on the implications of new psychoactive substances in public health, International journal of environmental research and public health 19 (2022) 4869.